2024-03-29T08:55:12Zhttps://repositori.uji.es/oai/requestoai:repositori.uji.es:10234/1656502024-03-25T09:12:40Zcom_10234_36080com_10234_9col_10234_36082
Repositori UJI
author
Sacristán, José Antonio
author
Lizán, Luis
author
Comellas, Marta
author
Garrido, Pilar
author
Avendaño, Cristina
author
Cruz-Hernández, Juan J.
author
Espinosa, Javier
author
Dilla, Tatiana
2017-01-25T08:22:43Z
2017-01-25T08:22:43Z
2016
SACRISTÁN, José A., et al. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Advances in Therapy, 2016, vol. 33, no 11, p. 2059-2068
0741-238X1865-8652
http://hdl.handle.net/10234/165650
http://dx.doi.org/10.1007/s12325-016-0415-5
Introduction
The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain.
Methods
Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs.
Results
A total of 188 individuals participated in the study. For all participants, when choosing treatments, the best rated characteristics were greater efficacy, greater safety, treatment adaptation to patients’ individual requirements and the rapid reincorporation of patients to their daily activities. There were important differences among participants in their opinion about survival, QoL and cost. In general, oncologists, patients, and the general population gave greater value to gains in QoL than healthcare policy makers. Compared to other participants healthcare policy makers gave greater importance to the economic impact related to oncology treatments.
Conclusions
Gains in QoL, survival, safety, cost and innovation are perceived differently by different groups of stakeholders. It is recommended to consider the perspective of different stakeholders in the assessment of a new cancer drugs to obtain more informed decisions when deciding on the most appropriate treatment to use
eng
The Author(s) 2016 Attribution-NonCommercial 4.0 International
clinically meaningful outcomes
innovation
oncology
Spain
value
Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology
info:eu-repo/semantics/article
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
URL
https://repositori.uji.es/xmlui/bitstream/10234/165650/1/75412.pdf
File
MD5
b4a5565e7962b919af3a8607ac7dbe0f
463419
application/pdf
75412.pdf
URL
https://repositori.uji.es/xmlui/bitstream/10234/165650/8/75412.pdf.txt
File
MD5
d5556dde11dedf942f6ca375a63f86c7
31122
text/plain
75412.pdf.txt